GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reiterated by equities research analysts at Liberum Capital in a report released on Monday. They presently have a GBX 1,700 ($22.21) price objective on the stock. Liberum Capital’s price target points to a potential upside of 12.84% from the company’s previous close.
A number of other equities research analysts have also commented on the company. Barclays reiterated an “overweight” rating on shares of GlaxoSmithKline in a research report on Monday, September 24th. Societe Generale set a GBX 1,000 ($13.07) price target on GlaxoSmithKline and gave the company a “sell” rating in a research report on Monday, September 10th. UBS Group reiterated a “buy” rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a research report on Thursday, September 27th. Jefferies Financial Group set a GBX 1,775 ($23.19) price target on GlaxoSmithKline and gave the company a “buy” rating in a research report on Thursday, August 16th. Finally, Shore Capital restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, September 10th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 1,521.27 ($19.88).
Shares of LON GSK traded up GBX 26.60 ($0.35) during trading on Monday, reaching GBX 1,506.60 ($19.69). The company had a trading volume of 3,528,193 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.